NMTC2
MCID: THY102
MIFTS: 64

Thyroid Cancer, Nonmedullary, 2 (NMTC2)

Categories: Cancer diseases, Endocrine diseases, Genetic diseases, Rare diseases

Aliases & Classifications for Thyroid Cancer, Nonmedullary, 2

MalaCards integrated aliases for Thyroid Cancer, Nonmedullary, 2:

Name: Thyroid Cancer, Nonmedullary, 2 58
Follicular Thyroid Carcinoma 12 54 30 6 15 17 74
Thyroid Carcinoma, Follicular 58 77 54 13
Thyroid Cancer, Follicular 54 74
Nmtc2 58 76
Follicular Adenocarcinoma, Well Differentiated 12
Follicular Carcinoma of the Thyroid Gland 12
Thyroid Carcinoma, Follicular, Somatic 58
Cancer, Thyroid, Nonmedullary, Type 2 41
Thyroid Cancer, Non-Medullary, 2 76
Thyroid Follicular Carcinoma 56
Thyroid Gland Adenocarcinoma 74
Adenocarcinoma, Follicular 45
Follicular Adenocarcinoma 12
Follicular Thyroid Cancer 56
Thyroid Adenocarcinoma 12
Follicular Carcinoma 12
Ftc 54

Characteristics:

OMIM:

58
Inheritance:
autosomal dominant
somatic mutation


HPO:

33
thyroid cancer, nonmedullary, 2:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

Disease Ontology 12 DOID:3962
OMIM 58 188470
NCIt 51 C8054
SNOMED-CT 69 28173006 5257006
SNOMED-CT via HPO 70 255028004 263681008

Summaries for Thyroid Cancer, Nonmedullary, 2

OMIM : 58 Nonmedullary thyroid cancer (NMTC) comprises thyroid cancers of follicular cell origin and accounts for more than 95% of all thyroid cancer cases. The remaining cancers originate from parafollicular cells (medullary thyroid cancer, MTC; 155240). NMTC is classified into 4 groups: papillary, follicular, Hurthle cell (607464), and anaplastic. Approximately 5% of NMTC is hereditary, occurring as a minor component of a familial cancer syndrome (e.g., familial adenomatous polyposis, 175100, Carney complex, 160980) or as a primary feature (familial NMTC or FNMTC). Papillary thyroid cancer (PTC) is the most common histologic subtype of FNMTC, accounting for approximately 85% of cases (summary by Vriens et al., 2009). Follicular thyroid cancer (FTC) accounts for approximately 15% of NMTC and is defined by invasive features that result in infiltration of blood vessels and/or full penetration of the tumor capsule, in the absence of the nuclear alterations that characterize papillary carcinoma. FTC is rarely multifocal and usually does not metastasize to the regional lymph nodes but tends to spread via the bloodstream to the lung and bones. An important histologic variant of FTC is the oncocytic (Hurthle cell, oxyphilic) follicular carcinoma composed of eosinophilic cells replete with mitochondria (summary by Bonora et al., 2010). For a general phenotypic description and a discussion of genetic heterogeneity of NMTC, see NMTC1 (188550). (188470)

MalaCards based summary : Thyroid Cancer, Nonmedullary, 2, also known as follicular thyroid carcinoma, is related to differentiated thyroid carcinoma and hyperthyroidism. An important gene associated with Thyroid Cancer, Nonmedullary, 2 is SRGAP1 (SLIT-ROBO Rho GTPase Activating Protein 1), and among its related pathways/superpathways are Focal Adhesion and Endometrial cancer. The drugs Iodine and Anti-Infective Agents have been mentioned in the context of this disorder. Affiliated tissues include thyroid, bone and lymph node, and related phenotypes are abnormality of metabolism/homeostasis and follicular thyroid carcinoma

Disease Ontology : 12 A thyroid carcinoma that has material basis in follicular cells.

UniProtKB/Swiss-Prot : 76 Thyroid cancer, non-medullary, 2: A form of non-medullary thyroid cancer (NMTC), a cancer characterized by tumors originating from the thyroid follicular cells. NMTCs represent approximately 95% of all cases of thyroid cancer and are classified into papillary, follicular, Hurthle cell, and anaplastic neoplasms.

Wikipedia : 77 Follicular thyroid cancer accounts for 15% of thyroid cancer and occurs more commonly in women over 50... more...

Related Diseases for Thyroid Cancer, Nonmedullary, 2

Diseases in the Thyroid Cancer, Nonmedullary, 2 family:

Thyroid Cancer, Nonmedullary, 1 Thyroid Cancer, Nonmedullary, 3
Thyroid Cancer, Nonmedullary, 4 Thyroid Cancer, Nonmedullary, 5

Diseases related to Thyroid Cancer, Nonmedullary, 2 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 143)
# Related Disease Score Top Affiliating Genes
1 differentiated thyroid carcinoma 32.7 TSHR TG RET PPARG PAX8 NRAS
2 hyperthyroidism 31.0 TSHR THRB TG
3 goiter 30.8 TSHR THRB TG PAX8 NKX2-1 LGALS3
4 graves disease 1 30.6 TSHR THRB TG DIO2
5 multinodular goiter 30.6 TSHR TG PAX8 NKX2-1 HRAS CALCA
6 papillary carcinoma 30.5 TSHR TG RET PAX8 NKX2-1 LGALS3
7 thyroid carcinoma, familial medullary 30.4 CALCA NKX2-1 RET TG
8 thyroid cancer 30.4 TSHR THRB TG SRGAP1 RET PTEN
9 struma ovarii 30.4 TSHR TG RET NKX2-1 BRAF
10 thyroiditis 30.3 TSHR THRB TG RET CALCA
11 adenocarcinoma 30.3 BRAF HRAS KDR PTEN RET
12 nontoxic goiter 30.3 CALCA TG TSHR
13 malignant struma ovarii 30.3 TG RET NRAS NKX2-1 LGALS3 HRAS
14 ovarian germ cell teratoma 30.2 TG RET NRAS NKX2-1
15 renal cell carcinoma, papillary, 1 30.2 PAX8 NRAS HRAS BRAF PTEN
16 gastric adenocarcinoma 30.1 BRAF HRAS KDR NRAS PTEN
17 anaplastic thyroid cancer 30.1 TG PTEN PAX8 NKX2-1 BRAF
18 follicular adenoma 30.0 TSHR TG RET PTEN PAX8 NKX2-1
19 hypothyroidism 29.8 TSHR THRB TG RET PAX8 NKX2-1
20 familial papillary or follicular thyroid carcinoma 12.3
21 trabecular follicular adenocarcinoma 12.2
22 papillary follicular thyroid adenocarcinoma 12.2
23 tumoral calcinosis, hyperphosphatemic, familial, 1 11.7
24 thyroid carcinoma, hurthle cell 11.2
25 tumoral calcinosis, hyperphosphatemic, familial, 2 11.1
26 tumoral calcinosis, hyperphosphatemic, familial, 3 11.1
27 giant congenital nevus 10.6 HRAS NRAS
28 ovarian melanoma 10.5 HRAS NRAS PTEN
29 mucoepidermoid thyroid carcinoma 10.5 CALCA TG
30 chromosome 14q11-q22 deletion syndrome 10.5 NKX2-1 HRAS
31 neonatal hypothyroidism 10.5 PAX8 TG TSHR
32 suppurative thyroiditis 10.5 TG CALCA
33 ovarian serous cystadenocarcinoma 10.5 BRAF HRAS NRAS
34 leukemia, chronic lymphocytic 2 10.5 BRAF HRAS NRAS
35 giant cell glioblastoma 10.5 BRAF PPARG PTEN
36 ovarian germ cell cancer 10.5 NKX2-1 RET TG
37 testicular germ cell tumor 10.5 PTEN HRAS BRAF
38 colloid adenoma 10.5 LGALS3 NKX2-1 TG
39 thyroid sarcoma 10.5 TG CALCA
40 toxic diffuse goiter 10.5 DIO2 TG TSHR
41 schimmelpenning-feuerstein-mims syndrome 10.5 NRAS HRAS
42 ovarian cystic teratoma 10.5 CALCA NKX2-1 TG
43 thyroid cancer, nonmedullary, 1 10.5
44 melanoma, cutaneous malignant 1 10.5 BRAF HRAS NRAS PTEN
45 water-clear cell adenoma 10.5 TG PAX8
46 respiratory system cancer 10.5 PTEN NKX2-1 HRAS
47 small cell carcinoma 10.5 CALCA NKX2-1 PTEN
48 spitz nevus 10.4 HRAS BRAF
49 parathyroid carcinoma 10.4 CALCA LGALS3 RET
50 suppression of tumorigenicity 12 10.4 PTEN HRAS BRAF

Graphical network of the top 20 diseases related to Thyroid Cancer, Nonmedullary, 2:



Diseases related to Thyroid Cancer, Nonmedullary, 2

Symptoms & Phenotypes for Thyroid Cancer, Nonmedullary, 2

Human phenotypes related to Thyroid Cancer, Nonmedullary, 2:

33
# Description HPO Frequency HPO Source Accession
1 abnormality of metabolism/homeostasis 33 HP:0001939
2 follicular thyroid carcinoma 33 HP:0006731
3 non-medullary thyroid carcinoma 33 HP:0040198

Symptoms via clinical synopsis from OMIM:

58
Neoplasia:
nonmedullary thyroid carcinoma (papillary and follicular)

Clinical features from OMIM:

188470

GenomeRNAi Phenotypes related to Thyroid Cancer, Nonmedullary, 2 according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.03 HRAS
2 Decreased viability GR00221-A-1 10.03 HRAS KDR NRAS PPARG RET
3 Decreased viability GR00221-A-2 10.03 HRAS KDR PPARG RET
4 Decreased viability GR00221-A-3 10.03 HRAS KDR NRAS PPARG
5 Decreased viability GR00221-A-4 10.03 KDR PPARG RET
6 Decreased viability GR00231-A 10.03 RET
7 Decreased viability GR00301-A 10.03 RET
8 Decreased viability GR00402-S-2 10.03 HRAS KDR NRAS PPARG RET
9 Reduced mammosphere formation GR00396-S 9.17 BRAF HRAS KDR NRAS PAX8 PPARG

MGI Mouse Phenotypes related to Thyroid Cancer, Nonmedullary, 2:

47 (show all 20)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.38 BRAF DIO2 HRAS KDR LGALS3 NKX2-1
2 behavior/neurological MP:0005386 10.36 BRAF HRAS KDR LGALS3 NKX2-1 NRAS
3 homeostasis/metabolism MP:0005376 10.36 BRAF DIO2 HRAS KDR LGALS3 NKX2-1
4 endocrine/exocrine gland MP:0005379 10.33 BRAF DIO2 HRAS NKX2-1 NRAS PAX8
5 cardiovascular system MP:0005385 10.32 BRAF HRAS KDR LGALS3 NKX2-1 NRAS
6 cellular MP:0005384 10.31 BRAF KDR LGALS3 NKX2-1 NRAS PAX8
7 digestive/alimentary MP:0005381 10.26 BRAF DIO2 HRAS LGALS3 NKX2-1 NRAS
8 mortality/aging MP:0010768 10.26 BRAF HRAS KDR LGALS3 NKX2-1 NRAS
9 hematopoietic system MP:0005397 10.22 BRAF KDR LGALS3 NRAS PPARG PTEN
10 nervous system MP:0003631 10.21 BRAF HRAS KDR LGALS3 NKX2-1 PAX8
11 neoplasm MP:0002006 10.16 BRAF HRAS LGALS3 NKX2-1 NRAS PPARG
12 limbs/digits/tail MP:0005371 10.1 BRAF NRAS PAX8 PTEN RET TG
13 adipose tissue MP:0005375 10.07 BRAF DIO2 LGALS3 PPARG PTEN TG
14 normal MP:0002873 10.07 BRAF HRAS KDR MINPP1 NKX2-1 NRAS
15 no phenotypic analysis MP:0003012 10.01 HRAS KDR NKX2-1 NRAS PAX8 PPARG
16 renal/urinary system MP:0005367 9.92 BRAF DIO2 HRAS LGALS3 PAX8 PPARG
17 reproductive system MP:0005389 9.91 BRAF LGALS3 NKX2-1 PAX8 PPARG PTEN
18 skeleton MP:0005390 9.77 BRAF DIO2 HRAS KDR LGALS3 NKX2-1
19 respiratory system MP:0005388 9.76 BRAF HRAS KDR LGALS3 NKX2-1 PTEN
20 vision/eye MP:0005391 9.23 BRAF KDR NRAS PAX8 PPARG PTEN

Drugs & Therapeutics for Thyroid Cancer, Nonmedullary, 2

Drugs for Thyroid Cancer, Nonmedullary, 2 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 138)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Iodine Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 7553-56-2 807
2 Anti-Infective Agents Phase 2, Phase 3,Phase 1,Not Applicable
3 Hormones Phase 3,Phase 2,Phase 1
4 cadexomer iodine Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable
5 Nutrients Phase 2, Phase 3,Phase 1,Not Applicable
6 Trace Elements Phase 2, Phase 3,Phase 1,Not Applicable
7 Anti-Infective Agents, Local Phase 2, Phase 3,Phase 1,Not Applicable
8 Micronutrients Phase 2, Phase 3,Phase 1,Not Applicable
9 Hormone Antagonists Phase 3,Phase 2
10 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2
11
Rosiglitazone Approved, Investigational Phase 2,Phase 1 122320-73-4 77999
12
Sirolimus Approved, Investigational Phase 2 53123-88-9 46835353 6436030 5284616
13
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
14
Everolimus Approved Phase 2 159351-69-6 6442177 70789204
15
Ritonavir Approved, Investigational Phase 2 155213-67-5 392622
16
Parathyroid hormone Approved, Investigational Phase 2,Phase 1 9002-64-6
17
Indinavir Approved Phase 2 150378-17-9 5362440
18
Azacitidine Approved, Investigational Phase 2,Phase 1 320-67-2 9444
19
Decitabine Approved, Investigational Phase 2 2353-33-5 451668
20
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
21
Lithium carbonate Approved Phase 2 554-13-2
22
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
23
Romidepsin Approved, Investigational Phase 2 128517-07-7 5352062
24
Vorinostat Approved, Investigational Phase 2 149647-78-9 5311
25
Celecoxib Approved, Investigational Phase 2 169590-42-5 2662
26
Gefitinib Approved, Investigational Phase 2,Not Applicable 184475-35-2 123631
27
Aldesleukin Approved Phase 2 85898-30-2, 110942-02-4
28
Sargramostim Approved, Investigational Phase 2 123774-72-1, 83869-56-1
29
Tamoxifen Approved Phase 2 10540-29-1 2733526
30
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
31
Cisplatin Approved Phase 2 15663-27-1 441203 84093 2767
32
Sodium Citrate Approved, Investigational Phase 2 68-04-2
33
Salmon Calcitonin Approved, Investigational Phase 2 47931-85-1 16129616
34
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
35
Lenvatinib Approved, Investigational Phase 2 417716-92-8
36
Pembrolizumab Approved Phase 2 1374853-91-4
37
Trametinib Approved Phase 2 871700-17-3 11707110
38
Lenalidomide Approved Phase 2,Phase 1 191732-72-6 216326
39
Dabrafenib Approved, Investigational Phase 2 1195765-45-7 44462760 44516822
40
Irinotecan Approved, Investigational Phase 1, Phase 2 100286-90-6, 97682-44-5 60838
41
Durvalumab Approved, Investigational Phase 2 1428935-60-7
42
Citric Acid Approved, Nutraceutical, Vet_approved Phase 2 77-92-9 311
43
SB-649868 Experimental, Investigational Phase 2,Phase 1 110-16-7, 110-17-8 444972
44
Doxil Approved June 1999 Phase 2 31703
45
Calcitonin gene-related peptide Investigational Phase 2 83652-28-2
46
Camptothecin Experimental Phase 1, Phase 2 7689-03-4
47
Cediranib Investigational Phase 1, Phase 2 288383-20-0 9933475
48
Tremelimumab Investigational Phase 2 745013-59-6
49 Hypoglycemic Agents Phase 2,Phase 1
50 Anti-Bacterial Agents Phase 2

Interventional clinical trials:

(show top 50) (show all 61)
# Name Status NCT ID Phase Drugs
1 A New Study to Follow-up Thyroid Cancer Patients Who Participated in a Previous Study, Which Compared the Success of Destruction of the Thyroid Remnant Using Standard Treatment or Thyrogen. Completed NCT00295763 Phase 3 Thyrogen (thyrotropin alfa for injection)
2 IoN- Is Ablative Radio-iodine Necessary for Low Risk Differentiated Thyroid Cancer Patients Recruiting NCT01398085 Phase 2, Phase 3
3 A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior VEGFR-targeted Therapy Recruiting NCT03690388 Phase 3 Cabozantinib;Placebo
4 High Dose vs Low Dose I 131 +/- rhTSH for Differentiated Thyroid Cancer Active, not recruiting NCT00415233 Phase 3
5 Rosiglitazone in Treating Patients With Locoregionally Extensive or Metastatic Thyroid Cancer Unknown status NCT00098852 Phase 2 rosiglitazone maleate
6 Everolimus in Treating Patients With Progressive or Recurrent, Unresectable, or Metastatic Thyroid Cancer Unknown status NCT01118065 Phase 2 everolimus
7 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
8 Decitabine in Treating Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Iodine I 131 Completed NCT00085293 Phase 2 Decitabine
9 Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy Completed NCT00104871 Phase 2 Bortezomib
10 Thalidomide in Treating Patients With Thyroid Cancer Completed NCT00026533 Phase 2 thalidomide
11 Effect of Lithium Carbonate on Low-Dose Radioiodine Therapy in Early Thyroid Cancer Completed NCT00251316 Phase 2 Lithium Carbonate;Placebo
12 Sutent Adjunctive Treatment of Differentiated Thyroid Cancer Completed NCT00668811 Phase 2 SU011248, Sutent
13 Romidepsin in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Has Not Responded to Radioactive Iodine Completed NCT00098813 Phase 2 romidepsin
14 Recombinant Thyrotropin PET-CT Fusion Scanning in Thyroid Cancer Completed NCT00181168 Phase 2 Euthyroid Group
15 Tanespimycin in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid Cancer Completed NCT00118248 Phase 2 tanespimycin
16 Aflibercept in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy Completed NCT00729157 Phase 2
17 Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer Completed NCT01811212 Phase 2 Cabozantinib S-malate
18 Sunitinib Malate in Treating Patients With Iodine-Refractory Recurrent or Metastatic Thyroid Cancer Completed NCT00519896 Phase 2 sunitinib malate
19 Suberoylanilide Hydroxamic Acid in Treating Patients With Metastatic and/or Locally Advanced or Locally Recurrent Thyroid Cancer Completed NCT00134043 Phase 2 vorinostat
20 Celecoxib in Treating Patients With Progressive Metastatic Differentiated Thyroid Cancer Completed NCT00061906 Phase 2 celecoxib
21 Gefitinib in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer That Did Not Respond to Iodine Therapy Completed NCT00095836 Phase 2 Gefitinib
22 Everolimus in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer Completed NCT01164176 Phase 2 everolimus
23 A Phase 2, Open-label Study of AMG 706 to Treat Subjects With Locally Advanced or Metastatic Thyroid Cancer Completed NCT00121628 Phase 2 AMG 706
24 Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors Completed NCT00019331 Phase 2 DetoxPC
25 Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors Completed NCT00002608 Phase 2 cisplatin;doxorubicin hydrochloride;tamoxifen citrate
26 Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer Recruiting NCT03630120 Phase 2 Lenvatinib;Sorafenib;Cabozantinib;Vandetanib
27 Lenvatinib and Iodine Therapy in Treating Patients With Radioactive Iodine-Sensitive Differentiated Thyroid Cancer Recruiting NCT03506048 Phase 2 Lenvatinib
28 Lenvatinib and Pembrolizumab in DTC Recruiting NCT02973997 Phase 2 Lenvatinib
29 Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer Recruiting NCT02393690 Phase 2 Selumetinib
30 Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer Recruiting NCT02152995 Phase 2 Trametinib
31 REVLIMID® (Lenalidomide) for Therapy of Radioiodine-Unresponsive Papillary and Follicular Thyroid Carcinomas Active, not recruiting NCT00287287 Phase 2 Lenalidomide
32 Efficacy and Safety of Vandetanib (ZD6474) in Patients With Metastatic Papillary or Follicular Thyroid Cancer Active, not recruiting NCT00537095 Phase 2 Vandetanib
33 Dabrafenib With or Without Trametinib in Treating Patients With Recurrent Thyroid Cancer Active, not recruiting NCT01723202 Phase 2 dabrafenib;trametinib
34 Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers Active, not recruiting NCT01631552 Phase 1, Phase 2 IMMU-132
35 Cediranib Maleate With or Without Lenalidomide in Treating Patients With Thyroid Cancer Active, not recruiting NCT01208051 Phase 1, Phase 2 Cediranib Maleate;Lenalidomide
36 Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery Active, not recruiting NCT00381641 Phase 2 Sunitinib Malate
37 Durvalumab Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma -The DUTHY Trial Not yet recruiting NCT03753919 Phase 2 Durvalumab;Tremelimumab
38 Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid Cancer Terminated NCT00095693 Phase 2 sorafenib tosylate
39 A Drug-Drug Interaction Study of the Effects of XL184 (Cabozantinib) on Rosiglitazone in Subjects With Solid Tumors Completed NCT01100619 Phase 1 rosiglitazone;XL184
40 Azacitidine to Restore Thyroid Function in Patients With Persistent or Metastatic Thyroid Cancer Completed NCT00004062 Phase 1 azacitidine;liothyronine sodium
41 Iodine I 131 and Pazopanib Hydrochloride in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer Previously Treated With Iodine I 131 That Cannot Be Removed By Surgery Completed NCT01413113 Phase 1 pazopanib hydrochloride
42 Photodynamic Therapy Using HPPH in Treating Patients Undergoing Surgery for Primary or Recurrent Head and Neck Cancer Completed NCT00470496 Phase 1 HPPH;photodynamic therapy
43 Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu Completed NCT00004074 Phase 1
44 Boronophenylalanine-Fructose Complex (BPA-F) and/or Sodium Borocaptate (BSH) Followed By Surgery in Treating Patients With Thyroid Cancer, Head and Neck Cancer, or Liver Metastases Completed NCT00062348 Phase 1 boronophenylalanine-fructose complex;sodium borocaptate
45 Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer Completed NCT00005842 Phase 1 tipifarnib
46 NGR-TNF in Treating Patients With Advanced Solid Tumors Completed NCT00098943 Phase 1
47 SU5416 and Paclitaxel in Treating Patients With Recurrent, Locally Advanced or Metastatic Cancer of the Head and Neck Completed NCT00005647 Phase 1 paclitaxel;semaxanib
48 S0716 Vandetanib and Docetaxel in Treating Patients With Advanced Solid Tumors Withdrawn NCT00937417 Phase 1 docetaxel;vandetanib
49 Biomarkers to Distinguish Benign From Malignant Thyroid Neoplasm Completed NCT01433809
50 Pre-Operative Nodal Staging of Thyroid Cancer Using USPIO MRI: Preliminary Study Completed NCT01927887 Not Applicable Ferumoxytol

Search NIH Clinical Center for Thyroid Cancer, Nonmedullary, 2

Cochrane evidence based reviews: adenocarcinoma, follicular

Genetic Tests for Thyroid Cancer, Nonmedullary, 2

Genetic tests related to Thyroid Cancer, Nonmedullary, 2:

# Genetic test Affiliating Genes
1 Follicular Thyroid Carcinoma 30

Anatomical Context for Thyroid Cancer, Nonmedullary, 2

MalaCards organs/tissues related to Thyroid Cancer, Nonmedullary, 2:

42
Thyroid, Bone, Lymph Node, Brain, Skin, Endothelial, Pituitary

Publications for Thyroid Cancer, Nonmedullary, 2

Articles related to Thyroid Cancer, Nonmedullary, 2:

(show top 50) (show all 432)
# Title Authors Year
1
Synchronous primary hyperparathyroidism, follicular thyroid carcinoma, and papillary thyroid carcinoma. ( 30614854 )
2019
2
Surgical management of follicular thyroid carcinoma in children and adolescents: A study of 30 cases. ( 29935896 )
2019
3
Follicular thyroid carcinoma metastatic to skin: a small papule and a big diagnostic change. ( 30726467 )
2019
4
Fine-needle aspiration cytology of metastatic spindle cell follicular thyroid carcinoma: A case report. ( 30794342 )
2019
5
Prediction of follicular thyroid carcinoma associated with distant metastasis in the preoperative and postoperative model. ( 30891875 )
2019
6
Tumour growth rate of follicular thyroid carcinoma is not different from that of follicular adenoma. ( 29509975 )
2018
7
A six-gene panel to label follicular adenoma, low- and high-risk follicular thyroid carcinoma. ( 29298844 )
2018
8
Pulmonary metastasis of mesonephric-like adenocarcinoma arising from the uterine body: a striking mimic of follicular thyroid carcinoma. ( 30471132 )
2018
9
Pulmonary Vein Thrombosis Associated with Metastatic Follicular Thyroid Carcinoma: A Case Report and Review. ( 30112241 )
2018
10
Follicular Thyroid Carcinoma in a Country of Endemic Iodine Deficiency (1994-2013). ( 29682275 )
2018
11
Comprehensive Genetic Analysis of Follicular Thyroid Carcinoma Predicts Prognosis Independent of Histology. ( 29726952 )
2018
12
A Case of Functional Metastatic Follicular Thyroid Carcinoma that Presented with Hip Fracture and Hypercalcemia. ( 29930932 )
2018
13
Follicular Thyroid Carcinoma: A Perspective. ( 30039751 )
2018
14
Follicular thyroid carcinoma within a thyroglossal duct cyst in adult. ( 30078030 )
2018
15
Neck Ultrasound in Patients with Follicular Thyroid Carcinoma. ( 30088223 )
2018
16
Calcaneus Metastasis from Follicular Thyroid Carcinoma 12 Years after Total Thyroidectomy. ( 30228920 )
2018
17
TERT Immunohistochemistry Is a Poor Predictor of TERT Promoter Mutations and Gene Expression in Follicular Thyroid Carcinoma. ( 30306386 )
2018
18
Preoperative sonographic features of follicular thyroid carcinoma predict biological behavior: A retrospective study. ( 30313115 )
2018
19
A Cardiac Metastasis of Follicular Thyroid Carcinoma With Partly Squamous Cell Differentiation: Detection in FDG-PET Preceded Visibility on Echocardiography and MRI by More Than a Year. ( 30325815 )
2018
20
Eighth edition of tumor-node-metastasis staging system improve survival predictability for papillary, but not follicular thyroid carcinoma: A multicenter cohort study. ( 30527251 )
2018
21
Cutaneous metastasis from Hürthle cell follicular thyroid carcinoma. ( 30551968 )
2018
22
Clinicopathologic and Molecular Features of Metastatic Follicular Thyroid Carcinoma in Patients Presenting With a Thyroid Nodule Versus a Distant Metastasis. ( 30557173 )
2018
23
A case of follicular thyroid carcinoma associated with phosphatase and tensin homologue hamartoma tumour syndrome. ( 30575166 )
2018
24
Thick tumor capsule is a valuable risk factor for distant metastasis in follicular thyroid carcinoma. ( 28506522 )
2018
25
Comparison of clinical characteristics of patients with follicular thyroid carcinoma and Hürthle cell carcinoma. ( 29433918 )
2018
26
LncRNA HCP5 promotes follicular thyroid carcinoma progression via miRNAs sponge. ( 29515098 )
2018
27
Bone metastases without primary tumor: A well-differentiated follicular thyroid carcinoma case. ( 29516937 )
2018
28
Importance of Number of Foci of Capsular Invasion in Follicular Thyroid Carcinoma. ( 29563727 )
2018
29
Overt Skeletal Metastases in a Patient of Occult (Microscopic) Follicular Thyroid Carcinoma: a Rare Case. ( 29563739 )
2018
30
CXCR4/CXCR7/CXCL12-Axis in Follicular Thyroid Carcinoma. ( 29581772 )
2018
31
Case report: Whole exome sequencing of circulating cell-free tumor DNA in a follicular thyroid carcinoma patient with lung and bone metastases. ( 29623111 )
2018
32
An upper cervical cord compression secondary to occult follicular thyroid carcinoma metastases successfully treated with multiple radioiodine therapies: A clinical case report. ( 29019888 )
2017
33
miR-146a and miR-146b promote proliferation, migration and invasion of follicular thyroid carcinoma via inhibition of ST8SIA4. ( 28427206 )
2017
34
A case of metastatic follicular thyroid carcinoma complicated with Graves' disease after total thyroidectomy. ( 28883260 )
2017
35
Prognostic Impact of Further Treatments on Distant Metastasis in Patients With Minimally Invasive Follicular Thyroid Carcinoma: Verification Using Inverse Probability of Treatment Weighting. ( 27272481 )
2017
36
Metastatic follicular thyroid carcinoma: a case report. ( 27384017 )
2017
37
Patterns of metastasis in follicular thyroid carcinoma and the difference between early and delayed presentation. ( 27659362 )
2017
38
Prognostic Impact of Further Treatments on Distant Metastasis in Patients with Minimally Invasive Follicular Thyroid Carcinoma: Verification Using Inverse Probability of Treatment Weighting. ( 27778073 )
2017
39
The total number of tissue blocks per centimetre of tumor significantly correlated with the risk of distant metastasis in patients with minimally invasive follicular thyroid carcinoma. ( 27928729 )
2017
40
Preoperative serum thyroglobulin and changes in serum thyroglobulin during TSH suppression independently predict follicular thyroid carcinoma in thyroid nodules with a cytological diagnosis of follicular lesion. ( 27936964 )
2017
41
Prognostic Impact of Further Treatments on Distant Metastasis in Patients with Minimally Invasive Follicular Thyroid Carcinoma: Verification Using Inverse Probability of Treatment Weighting. ( 28101608 )
2017
42
Follicular thyroid carcinoma presenting with pathological fracture of the humerus at initial diagnosis. ( 28108635 )
2017
43
Frontal bone metastasis from an occult follicular thyroid carcinoma: Diagnosed by FNAC. ( 28182063 )
2017
44
A 'silent' skull metastatic follicular thyroid carcinoma mimicking as a benign scalp tumor in a pregnant woman. ( 28203373 )
2017
45
Postoperative ultrasonography surveillance in patients with follicular thyroid carcinoma: a multicenter study. ( 28293811 )
2017
46
Follicular thyroid carcinoma metastasis to the facial skeleton: a systematic review. ( 28351395 )
2017
47
Metastatic Follicular Thyroid Carcinoma and the Primary Thyroid Gross Examination: Institutional Review of Cases from 1990 to 2015. ( 28444500 )
2017
48
Paediatric follicular thyroid carcinoma - indolent cancer with low prevalence of RAS mutations and absence of PAX8-PPARG fusion in a Japanese population. ( 28621837 )
2017
49
Follicular Thyroid Carcinoma Presenting as Large Solitary Vertebral Metastasis: Report of Two Unusual Cases Treated with Radiotherapy. ( 28695175 )
2017
50
Survivin and XIAP - two potential biological targets in follicular thyroid carcinoma. ( 28900184 )
2017

Variations for Thyroid Cancer, Nonmedullary, 2

UniProtKB/Swiss-Prot genetic disease variations for Thyroid Cancer, Nonmedullary, 2:

76
# Symbol AA change Variation ID SNP ID
1 HRAS p.Gln61Lys VAR_045979 rs28933406
2 MINPP1 p.Ser41Leu VAR_022836 rs119486096
3 MINPP1 p.Gln270Arg VAR_022837 rs104894171
4 NRAS p.Gln61Arg VAR_006847 rs11554290
5 SRGAP1 p.Gln149His VAR_075879 rs781626187
6 SRGAP1 p.Ala275Thr VAR_075880 rs797044990
7 SRGAP1 p.Arg617Cys VAR_075882 rs114817817
8 SRGAP1 p.His875Arg VAR_075883 rs61754221

ClinVar genetic disease variations for Thyroid Cancer, Nonmedullary, 2:

6 (show all 26)
# Gene Variation Type Significance SNP ID Assembly Location
1 SRGAP1 NM_020762.3(SRGAP1): c.447A> C (p.Gln149His) single nucleotide variant Pathogenic rs781626187 GRCh38 Chromosome 12, 64016970: 64016970
2 SRGAP1 NM_020762.3(SRGAP1): c.447A> C (p.Gln149His) single nucleotide variant Pathogenic rs781626187 GRCh37 Chromosome 12, 64410750: 64410750
3 SRGAP1 NM_020762.3(SRGAP1): c.823G> A (p.Ala275Thr) single nucleotide variant Pathogenic rs797044990 GRCh37 Chromosome 12, 64456718: 64456718
4 SRGAP1 NM_020762.3(SRGAP1): c.823G> A (p.Ala275Thr) single nucleotide variant Pathogenic rs797044990 GRCh38 Chromosome 12, 64062938: 64062938
5 SRGAP1 NM_020762.3(SRGAP1): c.1849C> T (p.Arg617Cys) single nucleotide variant risk factor rs114817817 GRCh37 Chromosome 12, 64502747: 64502747
6 SRGAP1 NM_020762.3(SRGAP1): c.1849C> T (p.Arg617Cys) single nucleotide variant risk factor rs114817817 GRCh38 Chromosome 12, 64108967: 64108967
7 MINPP1 NM_004897.4(MINPP1): c.122C> T (p.Ser41Leu) single nucleotide variant Pathogenic rs119486096 GRCh37 Chromosome 10, 89264794: 89264794
8 MINPP1 NM_004897.4(MINPP1): c.122C> T (p.Ser41Leu) single nucleotide variant Pathogenic rs119486096 GRCh38 Chromosome 10, 87505037: 87505037
9 MINPP1 NM_004897.4(MINPP1): c.809A> G (p.Gln270Arg) single nucleotide variant Pathogenic rs104894171 GRCh37 Chromosome 10, 89268264: 89268264
10 MINPP1 NM_004897.4(MINPP1): c.809A> G (p.Gln270Arg) single nucleotide variant Pathogenic rs104894171 GRCh38 Chromosome 10, 87508507: 87508507
11 HRAS NM_005343.3(HRAS): c.181C> A (p.Gln61Lys) single nucleotide variant Pathogenic/Likely pathogenic rs28933406 GRCh37 Chromosome 11, 533875: 533875
12 HRAS NM_005343.3(HRAS): c.181C> A (p.Gln61Lys) single nucleotide variant Pathogenic/Likely pathogenic rs28933406 GRCh38 Chromosome 11, 533875: 533875
13 NRAS NM_002524.4(NRAS): c.182A> G (p.Gln61Arg) single nucleotide variant Pathogenic rs11554290 GRCh37 Chromosome 1, 115256529: 115256529
14 NRAS NM_002524.4(NRAS): c.182A> G (p.Gln61Arg) single nucleotide variant Pathogenic rs11554290 GRCh38 Chromosome 1, 114713908: 114713908
15 BRAF NM_004333.5(BRAF): c.1801A> G (p.Lys601Glu) single nucleotide variant Pathogenic rs121913364 GRCh37 Chromosome 7, 140453134: 140453134
16 BRAF NM_004333.5(BRAF): c.1801A> G (p.Lys601Glu) single nucleotide variant Pathogenic rs121913364 GRCh38 Chromosome 7, 140753334: 140753334
17 HRAS NM_005343.4(HRAS): c.520C> T (p.Pro174Ser) single nucleotide variant Benign rs397517144 GRCh37 Chromosome 11, 532686: 532686
18 HRAS NM_005343.4(HRAS): c.520C> T (p.Pro174Ser) single nucleotide variant Benign rs397517144 GRCh38 Chromosome 11, 532686: 532686
19 PTEN NM_000314.7(PTEN): c.235G> A (p.Ala79Thr) single nucleotide variant Likely benign rs202004587 GRCh37 Chromosome 10, 89690828: 89690828
20 PTEN NM_000314.7(PTEN): c.235G> A (p.Ala79Thr) single nucleotide variant Likely benign rs202004587 GRCh38 Chromosome 10, 87931071: 87931071
21 PTEN NM_000314.6(PTEN): c.882T> G (p.Ser294Arg) single nucleotide variant Uncertain significance rs143335584 GRCh37 Chromosome 10, 89720731: 89720731
22 PTEN NM_000314.6(PTEN): c.882T> G (p.Ser294Arg) single nucleotide variant Uncertain significance rs143335584 GRCh38 Chromosome 10, 87960974: 87960974
23 PTEN NM_000314.6(PTEN): c.892C> G (p.Gln298Glu) single nucleotide variant Uncertain significance rs371387815 GRCh37 Chromosome 10, 89720741: 89720741
24 PTEN NM_000314.6(PTEN): c.892C> G (p.Gln298Glu) single nucleotide variant Uncertain significance rs371387815 GRCh38 Chromosome 10, 87960984: 87960984
25 PTEN NM_000314.6(PTEN): c.672del (p.Tyr225Ilefs) deletion Pathogenic GRCh38 Chromosome 10, 87957890: 87957890
26 PTEN NM_000314.6(PTEN): c.672del (p.Tyr225Ilefs) deletion Pathogenic GRCh37 Chromosome 10, 89717647: 89717647

Cosmic variations for Thyroid Cancer, Nonmedullary, 2:

9 (show top 50) (show all 1391)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM6961574 ZFHX3 thyroid,NS,carcinoma,papillary carcinoma c.5539C>T p.Q1847* 16:72797143-72797143 0
2 COSM7339522 ZBTB2 thyroid,NS,carcinoma,papillary carcinoma c.1012C>G p.P338A 6:151366054-151366054 0
3 COSM7339681 XPO1 thyroid,NS,carcinoma,papillary carcinoma c.1801C>G p.Q601E 2:61492121-61492121 0
4 COSM7340098 XPO1 thyroid,NS,carcinoma,papillary carcinoma c.994G>T p.E332* 2:61495508-61495508 0
5 COSM7339812 WT1 thyroid,NS,carcinoma,papillary carcinoma c.494C>G p.S165W 11:32428568-32428568 0
6 COSM6954354 VTCN1 thyroid,NS,carcinoma,papillary carcinoma c.399C>G p.I133M 1:117156620-117156620 0
7 COSM34008 VHL thyroid,NS,carcinoma,follicular carcinoma c.232A>T p.N78Y 3:10142079-10142079 0
8 COSM17721 VHL thyroid,NS,carcinoma,papillary carcinoma c.241C>T p.P81S 3:10142088-10142088 0
9 COSM26416 TSHR thyroid,NS,carcinoma,papillary carcinoma c.1867G>T p.A623S 14:81143925-81143925 0
10 COSM7340067 TSHR thyroid,NS,carcinoma,follicular carcinoma c.1859C>A p.T620N 14:81143917-81143917 0
11 COSM26497 TSHR thyroid,NS,carcinoma,papillary carcinoma c.1915C>T p.P639S 14:81143973-81143973 0
12 COSM26419 TSHR thyroid,NS,carcinoma,follicular carcinoma c.1897G>T p.D633Y 14:81143955-81143955 0
13 COSM26449 TSHR thyroid,NS,carcinoma,papillary carcinoma c.1358T>C p.M453T 14:81143416-81143416 0
14 COSM26455 TSHR thyroid,NS,carcinoma,follicular carcinoma c.1891T>A p.F631I 14:81143949-81143949 0
15 COSM26485 TSHR thyroid,NS,carcinoma,follicular carcinoma c.1894A>G p.T632A 14:81143952-81143952 0
16 COSM26417 TSHR thyroid,NS,carcinoma,papillary carcinoma c.1868C>T p.A623V 14:81143926-81143926 0
17 COSM26418 TSHR thyroid,NS,carcinoma,follicular carcinoma c.1895C>T p.T632I 14:81143953-81143953 0
18 COSM26450 TSHR thyroid,NS,carcinoma,follicular carcinoma c.1456A>T p.I486F 14:81143514-81143514 0
19 COSM7340068 TSHR thyroid,NS,carcinoma,papillary carcinoma c.572C>T p.S191L 14:81096665-81096665 0
20 COSM7339928 TSC2 thyroid,NS,carcinoma,papillary carcinoma c.4760G>A p.C1587Y 16:2086290-2086290 0
21 COSM6918838 TSC2 thyroid,NS,carcinoma,papillary carcinoma c.4468G>C p.E1490Q 16:2084690-2084690 0
22 COSM7340474 TSC2 thyroid,NS,carcinoma,papillary carcinoma c.4433A>T p.D1478V 16:2084655-2084655 0
23 COSM6955563 TSC1 thyroid,NS,carcinoma,follicular carcinoma c.257G>T p.R86L 9:132925693-132925693 0
24 COSM20429 TRRAP thyroid,NS,carcinoma,follicular carcinoma c.9809G>A p.R3270H 7:98993628-98993628 0
25 COSM7340048 TRRAP thyroid,NS,carcinoma,follicular carcinoma c.10688C>A p.S3563Y 7:99008440-99008440 0
26 COSM7340359 TRRAP thyroid,NS,carcinoma,papillary carcinoma c.7672A>C p.T2558P 7:98971853-98971853 0
27 COSM7339368 TRRAP thyroid,NS,carcinoma,follicular carcinoma c.9227T>C p.I3076T 7:98984957-98984957 0
28 COSM7340052 TRRAP thyroid,NS,carcinoma,follicular carcinoma c.776C>G p.A259G 7:98899743-98899743 0
29 COSM6472133 TRRAP thyroid,NS,carcinoma,follicular carcinoma c.8662C>T p.R2888C 7:98981871-98981871 0
30 COSM7340050 TRRAP thyroid,NS,carcinoma,follicular carcinoma c.4520C>T p.P1507L 7:98948267-98948267 0
31 COSM7340196 TP53BP1 thyroid,NS,carcinoma,papillary carcinoma c.910G>T p.E304* 15:43477623-43477623 0
32 COSM7339759 TP53BP1 thyroid,NS,carcinoma,follicular carcinoma c.3739C>A p.R1247S 15:43428090-43428090 0
33 COSM7340198 TP53BP1 thyroid,NS,carcinoma,papillary carcinoma c.5465G>T p.G1822V 15:43409017-43409017 0
34 COSM10648 TP53 thyroid,NS,carcinoma,follicular carcinoma c.524G>A p.R175H 17:7675088-7675088 0
35 COSM10659 TP53 thyroid,NS,carcinoma,papillary carcinoma c.817C>T p.R273C 17:7673803-7673803 0
36 COSM10704 TP53 thyroid,NS,carcinoma,papillary carcinoma c.844C>T p.R282W 17:7673776-7673776 0
37 COSM43951 TP53 thyroid,NS,carcinoma,papillary carcinoma c.643A>G p.S215G 17:7674888-7674888 0
38 COSM11196 TP53 thyroid,NS,carcinoma,papillary carcinoma c.734G>T p.G245V 17:7674229-7674229 0
39 COSM43723 TP53 thyroid,NS,carcinoma,papillary carcinoma c.398T>C p.M133T 17:7675214-7675214 0
40 COSM10662 TP53 thyroid,NS,carcinoma,papillary carcinoma c.743G>A p.R248Q 17:7674220-7674220 0
41 COSM10758 TP53 thyroid,NS,carcinoma,papillary carcinoma c.659A>G p.Y220C 17:7674872-7674872 0
42 COSM5444226 TP53 thyroid,NS,carcinoma,papillary carcinoma c.96+1G>C p.? 17:7676381-7676381 0
43 COSM44225 TP53 thyroid,NS,carcinoma,papillary carcinoma c.859G>A p.E287K 17:7673761-7673761 0
44 COSM10646 TP53 thyroid,NS,carcinoma,follicular carcinoma c.725G>A p.C242Y 17:7674238-7674238 0
45 COSM10739 TP53 thyroid,NS,carcinoma,papillary carcinoma c.481G>A p.A161T 17:7675131-7675131 0
46 COSM11183 TP53 thyroid,NS,carcinoma,follicular carcinoma c.799C>T p.R267W 17:7673821-7673821 0
47 COSM10654 TP53 thyroid,NS,carcinoma,papillary carcinoma c.637C>T p.R213* 17:7674894-7674894 0
48 COSM44922 TP53 thyroid,NS,carcinoma,papillary carcinoma c.670G>T p.E224* 17:7674861-7674861 0
49 COSM44338 TP53 thyroid,NS,carcinoma,papillary carcinoma c.845G>A p.R282Q 17:7673775-7673775 0
50 COSM10742 TP53 thyroid,NS,carcinoma,follicular carcinoma c.578A>G p.H193R 17:7674953-7674953 0

Expression for Thyroid Cancer, Nonmedullary, 2

Search GEO for disease gene expression data for Thyroid Cancer, Nonmedullary, 2.

Pathways for Thyroid Cancer, Nonmedullary, 2

Pathways related to Thyroid Cancer, Nonmedullary, 2 according to GeneCards Suite gene sharing:

(show all 29)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.8 BRAF HRAS KDR NRAS PTEN
2
Show member pathways
12.61 BRAF HRAS NRAS PAX8 PPARG PTEN
3
Show member pathways
12.6 BRAF HRAS KDR NRAS PTEN
4 12.53 BRAF HRAS NRAS PAX8 PPARG PTEN
5
Show member pathways
12.42 DIO2 HRAS PTEN THRB
6
Show member pathways
12.36 BRAF HRAS KDR NRAS PTEN
7
Show member pathways
12.3 BRAF HRAS NRAS PTEN
8 12.2 BRAF HRAS KDR NRAS
9
Show member pathways
12.16 BRAF HRAS NRAS PPARG
10
Show member pathways
12.11 HRAS KDR NRAS PTEN
11
Show member pathways
12.04 BRAF HRAS NRAS PPARG
12 12.03 HRAS KDR NRAS PTEN
13
Show member pathways
11.99 BRAF HRAS KDR NRAS PTEN
14
Show member pathways
11.96 BRAF HRAS NRAS PTEN
15 11.84 BRAF HRAS PTEN
16 11.84 DIO2 HRAS NRAS THRB
17 11.78 BRAF HRAS NRAS PTEN
18 11.66 BRAF HRAS NRAS
19
Show member pathways
11.59 BRAF HRAS NRAS
20 11.54 BRAF HRAS NRAS
21 11.48 HRAS NRAS PTEN RET
22 11.4 HRAS NRAS RET
23
Show member pathways
11.27 BRAF HRAS KDR NRAS RET
24 11.22 BRAF HRAS NRAS
25 11.11 HRAS NRAS PTEN
26 11.09 BRAF HRAS KDR NRAS
27 10.85 BRAF HRAS MIR197 PAX8 TSHR
28 10.74 HRAS NRAS
29 10.35 TG TSHR

GO Terms for Thyroid Cancer, Nonmedullary, 2

Biological processes related to Thyroid Cancer, Nonmedullary, 2 according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 cell differentiation GO:0030154 9.91 BRAF KDR LGALS3 PAX8 PPARG RET
2 positive regulation of gene expression GO:0010628 9.85 BRAF HRAS NKX2-1 PTEN RET
3 MAPK cascade GO:0000165 9.8 BRAF HRAS NRAS RET
4 hormone-mediated signaling pathway GO:0009755 9.58 PPARG THRB TSHR
5 animal organ morphogenesis GO:0009887 9.56 BRAF HRAS NKX2-1 THRB
6 hormone biosynthetic process GO:0042446 9.51 DIO2 TG
7 cellular response to nerve growth factor stimulus GO:1990090 9.5 BRAF CALCA PTEN
8 thyroid hormone metabolic process GO:0042403 9.48 DIO2 TG
9 regulation of axon regeneration GO:0048679 9.43 BRAF PTEN
10 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.26 BRAF HRAS KDR PTEN
11 thyroid-stimulating hormone signaling pathway GO:0038194 9.16 PAX8 TSHR
12 thyroid gland development GO:0030878 9.02 BRAF NKX2-1 PAX8 TG THRB
13 signal transduction GO:0007165 10.13 BRAF HRAS NRAS PPARG RET SRGAP1

Molecular functions related to Thyroid Cancer, Nonmedullary, 2 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signaling receptor activity GO:0038023 9.46 PPARG RET THRB TSHR
2 inositol-1,3,4,5-tetrakisphosphate 3-phosphatase activity GO:0051717 8.96 MINPP1 PTEN
3 thyroid-stimulating hormone receptor activity GO:0004996 8.62 PAX8 TSHR

Sources for Thyroid Cancer, Nonmedullary, 2

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....